MiR-487a performs oncogenic functions in osteosarcoma by targeting BTG2 mRNA. (13th May 2020)

• Record Type: Journal Article
• Authors: Gu, Zhiqian; Wu, Shaokun; Xu, Guoxing; Wu, Wei; Mao, Bo; Zhao, Shoujun
• Is Part Of: Acta biochimica et biophysica Sinica. Volume 52:Number 6(2020)
• Page Start: 631
• Page End: 637
• Publication Date: 2020-05-13
• Subjects: osteosarcoma -- miR-487a -- BTG2 -- proliferation -- invasion; Biochemistry -- Periodicals; Biophysics -- Periodicals; 572.05
• DOI: 10.1093/abbs/gmaa034
• Languages: English
• ISSNs: 1672-9145

Abstract

Abstract: Aberrant microRNA (miRNA) expression plays a critical role in osteosarcoma (OS) pathogenesis. In this study, we elucidated the involvement of miR-487a in OS and the underlying molecular mechanisms. We found that miR-487a was upregulated in OS clinical samples and cell lines. Knockdown of miR-487a suppressed OS cell growth and invasion and induced apoptosis; however, overexpression of miR-487a promoted OS cell growth and invasion. Accordingly, downregulation of miR-487a significantly suppressed tumor growth of OS xenografts in vivo . Furthermore, B-cell translocation gene 2 ( BTG2 ) mRNA was found to be a novel target of miR-487a. Knockdown of BTG2 using small interfering RNA (siRNA) recapitulated the oncogenic effects of miR-487a, whereas BTG2 overexpression partially reversed these effects. Finally, miR-487a levels were found to be negatively correlated with BTG2 expression in OS clinical samples. Collectively, our data suggest that miR-487a is an oncogenic miRNA in OS and it lowers BTG2 expression.